Skip to main content

The Institute of Oncology aims its activities in the areas of scientific research, educational work as well as the promotion of academic degrees and continuous education in the fields of oncology and personalised medicine. One of the important goals of the Institute is to encourage the awareness of hereditary and sporadic oncological diseases among health care specialists and the general public.

The Institute of Hereditary Cancer was established in 2001 by Riga Stradins University in collaboration with Professor Jan Lubinski (Pomeranian Medical University, Szczecin, Poland). The first director of the Institute was Professor Jānis Gardovskis. Since then the Institute has expanded its activities and research fields to become the Institute of Oncology in 2012.

The Institute of Oncology is involved in national and international grants, cooperation programmes, scientific projects and clinical trials, provides support for students, residents in training and doctoral students in their research work.

Departments of the Institute

Tumour Chemistry and Laser Therapy Research Department

Chemotherapy is one of the options in cancer treatment using potent chemical substances. Usually it includes the whole body, though specific organs or tissues can be targeted. The aim of chemotherapy is to fight a cancer:

  • by reducing a size of the tumour before surgery or radiotherapy;
  • in the case of prophylactic chemotherapy to eliminate cancer cells from surrounding organs or tissues after surgery;
  • to relieve symptoms of disease or to control tumour growth.

Radiotherapy is the medical use of ionising radiation as part of cancer treatment to control or kill malignant cells. Although healthy tissues can be affected by therapy, they recover more quickly than tumour cells.

Recently cancer treatment became more personalised with options to use chemotherapy for specific tumour types. Immunohistochemistry tumour markers are indicative of particular tumour sub-types based on individual features and can be used for more precise diagnostics, prediction of therapy efficiency and increase of the life expectancy of patients.

Breast Cancer Research Department

Main goals of the Department:

  • Clinical studies — hereditary cancer diagnosis, treatment and prevention research;
  • To encourage patients to be aware of breast cancer development, prevention and early diagnostics.

Clinical research work  is conducted in cooperation with Pauls Stradiņš Clinical University Hospital, Breast Unit.

Laboratory of Molecular Genetics

Main research activities of the Laboratory:

  • Molecular genetics studies — identification of hereditary and sporadic tumour mutations by a wide spectrum of molecular biology methods from PCR to NGS (Next Generation Sequencing);
  • Study of tumour biomarkers — research of potential biomarkers with prognostic and predictive significance:
    • analysis of microRNA expression level changes in the tissues of tumours to assess the efficiency of therapy;
    • LOH and CNV analysis in the tissues of tumours;
    • analysis of circulating nucleic acids in metastatic breast and colorectal cancer patients plasma/serum.
  • The Biobank at the Institute of Oncology is a repository of over 14,000 DNA samples from breast, colorectal and other cancer patients and control groups, as well as more than 500 freshly-frozen breast cancer tissue samples.
Onco-urology Research Department

The Department is focused on urological oncology disorders – kidney, prostate and bladder cancers, their clinical and molecular genetics research, to promote more efficient and early diagnostics of the disease.

Study of therapeutic efficiency is performed to provide better results in cancer treatment.

Clinical research work is conducted in cooperation with Pauls Stradins Clinical University Hospital, Urology Centre.

Hereditary Cancer Research Department

Main goals of the Department:

  • Clinical studies of hereditary oncology diseases, their diagnostic and treatment results, as well as prevention;
  • Encourage patients to be aware of gene mutation inheritance, prevention and early diagnostics of the disease;
  • Development of database for clinical, molecular genetics and statistical data of hereditary tumours.

The clinical work of research is done in cooperation with Pauls Stradiņš Clinical University Hospital, Hereditary Cancer Cabinet.

Sociology and Life Quality Analysis Department

Main goals of the Department:

  • Study of breast cancer patients quality of life, experience and various social aspects related to the disease;
  • Analyse the treatment, quality and availability of health care and personal assessment of various support types;
  • Data analysis of sociological research in relation to genetic and clinical data, to obtain comprehensive information about the causes, risk factors, and course of the disease.

Projects

Projects funded by the Latvian Council of Science and National Research Programme
  • Biomarkers of altered gut microbiome in children with autism spectra disorders, No. Izp-2018/2-0343. Duration: 2018–2020
  • The National Research Programme "Biomedicine for Public Health (BIOMEDICINE)", project No. 5.5 "Personalized cancer diagnostics and prediction of therapy efficacy". Duration: 2014–2017
  • Within the framework of the National Research Programme “Development of New Preventive, Treatment, Diagnostic Means and Methods, Biomedical Technologies for Improvement of Public Health” — project No. 4 “Study of clinical, molecular, and morphological correlation, early diagnosis, treatment effectiveness and patients’ quality of life of hereditary and sporadic cancer”. Duration: 2010–2014
  • Project of the Administration of Studies and Research No. 09.1603 “Strategy for Treatment of Life Expectancy and Life Quality Threatening Diseases”. Duration: 2009–2012
  • Within the framework of the National Research Programme “Study of Major Pathologies Threatening the Life Expectancy and Quality of Life in the Latvian Population by Multi-Disciplinary Research Consortium” – project “Clinical and molecular study of hereditary cancers for prevention and development of early diagnostics strategy”. Duration: 2006–2009
  • Project of the Administration of Studies and Research RSU-ZP 07-5 “Clinical and molecular studies of malignant cancers for the improvement of early diagnostics and therapeutic strategy”. Duration: 2007–2008
  • Project funded by the Latvian Council of Science No. 05.1838. “Clinical and molecular characteristics of hereditary breast and ovarian cancer in Latvia”. Duration: 2005–2008
  • Postdoctoral project funded by the Latvian Council of Science No. 05.1840. “Clinical manifestations and molecular characteristics of the predisposed gene mutations with high and low penetrance in colorectal cancer”. Duration: 2005–2008
Bilateral projects
  • ERA-NET TRANSCAN projects "Mutated neo-antigens in hepatocellular carcinoma" (HEPAMUT). 2017–2020
  • ERA-NET FLAGERA projects "Information Technology: The Future of Cancer Treatment” (ITFoC). 2017–2020
  • European Social Fund co-financed project No. 1DP/1.1.1.2.0/13/APIA/VIAA/017. “Predictive test to evaluate efficacy of therapy of oncological patients”. Duration: 2014–2015
  • Project No. ESTLATRUS/3.2./ELRI-097/2011/06 “Formation of Hereditary Cancer Prevention Measures in Pskov Region” co-financed by the programme “Estonia-Latvia-Russia Cross-border Collaboration 2007–2013”. Duration: 2012–2013
  • Project No. LLB-1-090 „The Development of modern breast cancer awareness, prevention, early detection and management measures in border regions of Latvia, Lithuania and Belarus” co-financed by the programme "Latvia-Lithuania-Belarus cross-border collaboration 2007-2013". Duration: 2011–2013
  • European Social Fund co-financed project No. 2009/0230/1DP/1.1.1.2.0/09/APIA/VIAA/070. “Creation of a new interdisciplinary research team to investigate breast cancer and to increase the efficacy of therapy and the patient’s quality of life”. Duration: 2010–2013

Publications

2019
  • Hilz P., Heinrihsone R., Pätzold L.A., Qi Qi, Trofimovics G., Gailite L., Irmejs A., Gardovskis J., Miklasevics E., Daneberga Z., Allelic variants of breast cancer susceptibility genes PALB2 and RECQL in the Latvian population. Hered. Cancer Clin. Pract., 2019; 17:17. DOI:10.1186/s13053-019-0116-6
  • Daneberga Z., Berzina D., Borosenko V.,  Krumina Z.,  Kokaine-Sapovalova L., Gardovskis A., Berga-Svitina E., Gardovskis J., Miklasevics E., Pathogenic APC Variants in Latvian Familial Adenomatous Polyposis Patients. Medicina, 2019; 55, 612. DOI: https://www.mdpi.com/1010-660X/55/10/612
  • Pirsko V., Cakstina I., Nitisa D., Samovica M., Daneberga Z., Miklasevics E. Alterations of the stem-like properties in the breast cancer cell line MDA-MB-231 induced by single pulsed doxorubicin treatment. Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences, 2019; 73; 2; 20–30. doi.org/10.2478/prolas-2019-0015
  • Licite B., Irmejs A., Maksimenko J., Loza P., Trofimovics G., Miklasevics E., Nazarovs J., Romanovska M., Deicmane J., Purkalne G., Gardovskis J. Role of percutaneous needle biopsy of axillary lymph nodes to evaluate node positive breast cancer after neoadjuvant chemotherapy. Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences, 2019, 73, 4; 368-372. doi.org/10.2478/prolas-2019-0057
  • Laizane G., Ķivite A., Grope I., Smane L., Miklaševičs E., Ozoliņa, Gardovska D. Clinical characterisation of rota virus infection associated with most commonly circulating genotypes in children hospitalised in children's university hospital: A cross-sectional study in Latvia. Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences, 2019, 73, 4; 312-316. DOI: https://doi.org/10.2478/prolas-2019-0049
  • Ukleikins S., Irmejs A., Gilis A, Tauvena E., Maksimenko J., Trofimovičs G., Body mass index and nipple preservation are major contributors to satisfaction and aesthetic outcome rates after implant-based immediate breast reconstruction. Contemp. Oncol. (Pozn), 2019, 23, 2; 96-99. DOI: https://doi.org/10.5114/wo.2019.85881
  • Skuja E., Butane D., Nakazawa-Miklasevica M., Daneberga Z., Purkalne G., Miklasevics E. Deletions in metastatic colorectal cancer with chromothripsis. Exp. Oncol., 2019, 41(4):323-327. DOI:10.32471/exp-oncology.2312-8852.vol-41-no-4.13841
2018
  • Pirsko V., Cakstina  I., Priedite M., Dortane R., Feldmane L., Nakazawa-Miklasevica M., Daneberga Z., Gardovskis J., Miklasevics E. An effect of culture media on epithelial differentiation markers in breast cancer cell lines MCF7, MDA-MB-436 and SkBr3. Medicina  (Kaunas), 2018, 54, 11; DOI:10.3390/medicina54020011
  • Sæther NH., Skuja E., Irmejs A., Maksimenko J., Miklasevics E., Purkalne G., Gardovskis J. Platinum-based neoadjuvant chemotherapy in BRCA1-positive breast cancer: a retrospective cohort analysis and literature review. Hered. Cancer Clin. Pract., 2018, 16:9. DOI:10.1186/s13053-018-0092-2
  • Maksimenko J., Irmejs A., Trofimovičs G., Bērziņa D., Skuja E., Purkalne G., Miklaševičs E., Gardovskis J. High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population. Heredi. Cancer Clin. Pract., 2018, 16:12. DOI:10.1186/s13053-018-0094-0
  • Markoczy  Z., Sarosi V., Kudaba I., Galffy G., Turay U. Y., Demirkazik  A., Purkalne G., Somfay A., Papai-Szekely  Z., Raso  E., Ostoros  G. Erlotinib as single agent first line treatment in locally advanced or metastatic activating EGFR mutation-positive lung adenocarcinoma (CEETAC): an open-label, non-randomized, multicenter, phase IV clinical trial; BMC CANCER, 2018; 25;18, 598 DOI:10.1186/s12885-018-4283-z
2017
  • Pätzold L.A., Bērziņa D., Daneberga Z., Gardovskis J., Miklaševičs E. Detection of allelic variants of the POLE and POLD1 genes in colorectal cancer patients. BJMG, 2017, 20, 83-88. DOI:10.1515/bjmg-2017-0028
  • Ivbule M., Miklaševičs E., Čupane, L., Berziņa L., Balinš A., Valdovska, A. Presence of methicillin-resistant Staphylococcus aureus in slaughterhouse environment, pigs, carcasses, and workers. Journal of Veterinary Research (Poland) Volume 61, Issue 3, September 2017, Pages 267-277.: SCOPUS
  • Ivbule M., Miklaševičs E., Čupane, L., Berziņa L., Baliņš A., Valdovska A. MRSA in pig population. Polish Journal of Microbiology, Volume 66, Issue 3, 2017, Pages 383-392..; SCOPUS
  • Ivbule M., Miklaševičs E., Čupanec L., Berziņa L., Balinš A., Valdovska A. Investigation of mrsa isolates from pig orgin, environemnt and stuffby SPA typing, antimirobial resistance and se gene detection. Veterinaria ir Zootechnika, Volume 75, Issue 97, 2017, Pages 6-16.; SCOPUS
  • Skuja E., Kalniete D., Nakazawa-Miklasevica M., Daneberga Z., Abolins A., Purkalne G., Miklasevics E Chromothripsis and progression-free survival in metastatic colorectal cancer. Mol. Clin. Oncol., 2017, 2, 82-186.; SCOPUS
  • Irmejs A, Loza P, Skuja E, Gardovskis J. Cureus. Platinum-Based Chemotherapy Secures Effective Local Control for Very Advanced Hereditary Triple-Negative Breast Cancer with Life-Threatening Bleeding. 2017 Jul 10;9(7):e1455. doi: 10.7759/cureus.1455; SCOPUS
2016
  • Narkevica I, Stipniece L, Jakobsons E, Cakstina I, Ozolins J. Electrically active and 3D porous TiO2-x ceramic scaffolds for bone tissue regeneration. Journal of the European Ceramic Society. 2016; 37:833-840, https://doi.org/10.1016/j.jeurceramsoc.2016.09.032
  • Plonis J, Kalniete D, Nakazawa-Miklasevica M, Irmejs A, Vjaters E, Gardovskis J, Miklasevics E. The CHEK2 del5395 is a founder mutation without direct effects for cancer risk in the latvian population. Balkan J Med Genet., 2016; 18(2):33-36, https://doi.org/10.1515/bjmg-2015-0083
2015
  • Kalniete D., Nakazawa-Miklasevica M., Strumfa I., Abolins A., Irmejs A., Gardovskis J., Miklasevics E. High expression of mir-214 is associated with worse disease-specific survival of the triple-negative breast cancer patients. Hereditary Cancer in Clinical Practice 2015, 2015, 13:7.
  • Plonis J., Nakazawa-Miklasevica M., Malevskis A., Vaganovs P., Pildava S., Vjaters E., Gardovskis J., Miklasevics E. Survival rates of familial and sporadic prostate cancer patients. Exp. Oncol., 2015, 37, 154 - 155.
  • Serrano-Fernandez P., Dymerska D., Kurzawski G., Derkacz R., Sobieszczanska T., Banaszkiewicz Z., Roomere H., Oitmaa E., Metspalu A., Janavicius R., Elsakov P., Razumas M., Petrulis K., Irmejs A., Miklaševics E., Rodney J. S., Lubinski J. Cumulative small effect genetic markers and the risk of colorectal cancer in Poland, Estonia, Lithuania and Latvia. Gastroenterology Res. Practice, 2015, Article ID 204089.
  • Ustinova M., Daneberga Z., Bērziņa D., Nakazawa-Miklaševiča M., Maksimenko J., Gardovskis J., Miklaševičs E. Impact of KRAS variant rs61764370 on breast cancer morbidity. Exp. Oncol., 2015, 37, 292 - 294.
  • Zanda Daneberga, Elza Broka, Dagnija Kalniete, Miki Nakazawa-Miklasevica, Monta Ustinova, Elina Skuja, Gunta Purkalne, Edvins Miklasevics. Plasma miR-21 and miR-31 as Predictive Biomarkers for Evaluation of Therapeutic Efficacy in Metastatic Colorectal Cancer, 2015, ACTA CHIRURGICA LATVIENSIS, 15/1: 3-7.
  • Edvins Miklasevics, Mikko Kupila, Dagnija Kalniete, Inese Eglite, Dace Berzina, Monta Ustinova, Gunta Purkalne, Zanda Daneberga. Chromosomal Aberration in Colorectal Cancer Family, 2015, ACTA CHIRURGICA LATVIENSIS, 15/1: 8-11.
2014
  • Pogodina J., Ribenieks R., Berzina D., Trofimovics G., Miklasevics E. CDH1 mutation in two patients with hereditary gastric cancer. Acta Chirurgica Latviensis, 2014, N14/1, 35 - 37.
  • Dymerska D., Kurzawski G., Suchy J., Roomere H., Toome K., Metspalu A., Janavičius R., Elsakov P., Irmejs A., Berzina D., Miklaševičs E., Gardovskis J., Rebane E., Kelve M., Kładny J., Huzarski T., Gronwald J., Dębniak T., Byrski T., Stembalska A., Surdyka D., Siołek M., Szwiec M., Banaszkiewicz Z., Wiśniowski R., Kilar E., Scott R., Lubiński J. Lynch syndrome mutations shared by the Baltic States and Poland. Clin. Genet., 2014, 86, 190 - 193.
  • Reste J., Zvigule G., Zvagule T., Kurjane N., Eglite M., Gabruseva N., Berzina D., Plonis J., Miklasevics E. Telomere length in Chernobyl accident recovery workers in the late period after the disaster. J. Radiat. Res., 2014, 55, 1089 - 1100.
  • Plonis J., Bokums K., Cauce V., Miklasevics E., Vaganovs P., Irmejs A., Gardovskis J., Vjaters E. Prostate cancer trends in Latvia during 1990 - 2012: Incidence, prevalence, mortality and survival rates. Medicina (Kaunas), 2014, 50, 313 - 317.
  • Pranka M., Dzervite A., Rungule R., Lace T., Miklasevics E., Gardovskis J. Assessment of life quality factors by breast cancer patients. SHS Web of Conferences: Proceedings. - vol. 10 (2014): 4th International Interdisciplinary Scientific Conference “Society. Health. Welfare” (Riga, Latvia, Nov. 22 - 23, 2012) / - 00034-p.1-00034-p10.
  • Svampane L., Strumfa I., Berzina D., Svampans M., Miklasevics E., Gardovskis J. Epidemiological analysis of hereditary endometrial cancer in a large study population. Arch. Gynecol. Obstet., 2014, Epub ahead of print.
  • Maksimenko J., Irmejs A., Nakazawa-Miklasevica M., Melbarde-Gorkusa I., Trofimovics G., Gardovskis J., Miklasevics E. Prognostic role of BRCA1 mutations in patients with triple-negative breast cancer. Oncology Letters, 2014, 7, 278 - 284.
  • Skuja E., Sorubalko A., Purkalne G., Miklasevics E. Neoadjuvant Chemoradiation in Patient with Localy Advanced Rectal Cancer. Acta Chirurgica Latviensis, 2014 (13/1)
2013
  • Dymerska D., Kurzawski G., Suchy J., Roomere H., Toome K., Metspalu A., Janavičius R., Elsakov P., Irmejs A., Berzina D., Miklaševičs E., Gardovskis J., Rebane E., Kelve M., Kładny J., Huzarski T., Gronwald J., Dębniak T., Byrski T., Stembalska A., Surdyka D., Siołek M., Szwiec M., Banaszkiewicz Z., Wiśniowski R., Kilar E., Scott R., Lubiński J. Lynch syndrome mutations shared by the Baltic States and Poland. Clin Genet. 2013; 5. DOI: 10.1111/cge.12251
  • Kalniete D., Nakazawa-Miklasevica M., Strumfa I., Abolins A., Irmejs A., Trofimovics G., Gardovskis J., Miklasevics E. MicroRNA Expression in Different Sybtypes of Breast Cancer. Acta Chirurgica Latviensis, 2013; 13, (1): 7–12. DOI: 10.2478/chilat-2013-0002
  • Dzervite A., Pranka M., Lace T., Rungule R., Gardovskis J., Miklasevics E. Initial Findings of Breast Cancer Risk Factors from a Survey Conducted at Pauls Stradins Clinical University Hospital. Acta Chirurgica Latviensis, 2013; 13, (1): 34–38. DOI: 10.2478/chilat-2013-0007
  • Pogodina J., Trofimovics G., Miklasevics E., Ribenieks R. Hereditary Gastric Cancer: Review of Literature. Acta Chirurgica Latviensis. 2013; 13, (1): 71–74. DOI: 10.2478/chilat-2013-0013
  • Vaganovs P., Bokums K., Miklaševics E., Plonis J., Zarina L., Geldners I., Gardovskis J., Vjaters E. Von hippel-lindau syndrome: diagnosis and management of hemangioblastoma and pheochromocytoma. Case Rep Urol., 2013. PMID: 23781388
  • Berzina D., Nakazawa-Miklasevica M., Zestkova J., Aksenoka K., Irmejs A., Gardovskis A., Kalniete D., Gardovskis J., Miklasevics E. BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families. BMC Med Genet, 2013; 14(1):61. PMID: 23767878
  • Plakhins G., Gardovskis A., Subatniece S., Liepniece-karele I., Purkalne G., Teibe U., Trofimovičs G., Miklaševičs E., Gardovskis J. Underestimated survival predictions of the prognostic tools Adjuvant! Online and PREDICT inBRCA1 – associated breast cancer patients. Fam Cancer, 2013; 3. PMID: 23640109
  • Saule M., Samuelsen Ø., Dumpis U., Sundsfjord A., Karlsone A., Balode A., Miklasevics E., Karah N. Dissemination of a carbapenem-resistant Acinetobacter baumannii strain belonging to international clone II/sequence type 2 and harboring a novel AbaR4-like resistance island in Latvia. Antimicrob Agents Chemother. 2013; 57(2):1069-72. PMID: 23229482
  • Svampane L., Strumfa I., Berzina D., Svampans M., Miklasevics E., Gardovskis J. Epidemiological analysis of hereditary endometrial cancer in a large study population. Arch Gynecol Obstet. 2013. PMID: 24292105
2012
  • Vanags A., Štrumfa I., Gardovskis A., Āboliņš A., Simtniece Z., Trofimovičs G., Gardovskis J., The first evidence of hereditary and familial gastric cancer in Latvia: implications for prevention. Medicina (Kaunas), 2012; 48: 317–323. PMID: 22885366
  • Melbārde-Gorkuša I., Irmejs A., Bērziņa D., Strumfa I., Aboliņš A., Gardovskis A., Subatniece S., Trofimovičs G., Gardovskis J., Miklaševičs E. Challenges in the management of a patient with Cowden syndrome: case report and literature review. Hered Cancer Clin Pract, 2012; 14, 10 (1):5. PMID: 22503188
  • Tulin A., Ribenieks R., Pogodina J., Stucka R., Shavlovskis J., Gardovskis J., Diagnostics and surgical treatment of liver echinococcosis in Latvia. Vestn Khir Im I I Grek, 2012;171(1):38-44. PMID:22645914PMID: 22645914
  • Simtniece Z., Strumfa I., Abolins A, Vanags A., Gardovskis J. Prognostic factors after curative resection of pancreatic ductal adenocarcinoma: a retrospective study. Journal of Cancer Therapeutics and Research, 2012. DOI: HTR
  • Skuja E., Āboliņš A., Priedīte I., Purkalne G., Štrumfa I., Vilmanis J., Kalniete D., Miklaševičs E., Gardovskis J. Pathological Complete Remission in Young Colon Cancer Patient with a Large Liver Metastasis after FOLFOX-4/Bevacizumab Treatment—A Case Report. Int. J. Clinical Med., 2012; 3: 307-310. IJCM2012
  • Ozolins A., Narbuts Z., Strumfa I., Volanska G., Stepanovs K., Gardovskis J. Immunohistochemical Expression of HBME-1, E-cadherin, and CD56 in the Differential Diagnosis of Thyroid Nodules. Medicina (Kaunas), 2012;48(10):507-14. PMID: 23324246
  • Bērziņš D., Irmejs A., Kalniete D., Borošenko V., Nakazawa-Miklasevica M., Rībenieks K., Trofimovič G., Gardovskis J., Miklaševič E. Novel germline MLH1 and MSH2 mutations in Latvian Lynch syndrome families. Exp. Oncol., 2012; 34, 1–4. PMID: 22453149
  • Čupāne L., Pugačova Ņ., Bērziņa D., Cauce V., Gardovska D., Miklaševičs E. Patients with PVL positive S. aureus infections run an increased risk of longer hospitalisation. Int. J. Mol. Epidemiol. Genet., 2012; 3(1), 48–55. PMID: 22493751
  • Dzērvīte A., Pranka M., Lace T., Rungule R., Miklasevics E., Gardovskis J. Key Factors Contributing to Quality of Life for Breast Cancer Patients in Latvia: Supplementing Quantitative Surveys with Qualitative Interviews. Acta Chirurgica Latviensis, 2012; 12, (1): 3–10. DOI: 10.2478/v10163-012-0001-0
  • Maksimenko J., Irmejs A., Trofimovics G., Miklasevics E. Breast – conserving Surgery in Early – Stage Triple – Negative Breast Cancer: Is There a Higher Risk of Locoregional Recurrence? Acta Chirurgica Latviensis, 2012; 12,(1):11–14. DOI: 10.2478/v10163-012-0002-z
  • Skuja E., Purkalne G., Miklasevics E. Unresectable Metastatic Colorectal Cancer Treatment and Survival – Pauls Stradins Clinical University Hospital Experience. Acta Chirurgica Latviensis, 2012; 12, (1):15–19. DOI: 10.2478/v10163-012-0003-y
  • Strumfa I., Vanags A., Abolins A., Gardovskis J. Pathology of Breast Cancer: from Classic Concepts to Molecular Pathology and Pathogenesis. Acta Chirurgica Latviensis, 2012; 12 (1):59–66. DOI: 10.2478/v10163-012-0012-x
  • Vanags A., Sneidere M., Strumfa I., Simtniece Z., Pavars M., Gardovskis J. Recurrent Gallstone Ileus in an Elderly Patient With Significant Co-Morbidity. Acta Chirurgica Latviensis, 2012; 12, (1):78–80. DOI: 10.2478/v10163-012-0015-7
  • Abolins A., Strumfa I., Vanags A., Trofimovics G., Gardovskis J. Granular Cell Tumour of the Breast Cancer: Challenging Clinical and Radiological Mimic of Cancer. Acta Chirurgica Latviensis, 2012; 12, (1):84–86. DOI: 10.2478/v10163-012-0017-5
  • Simtniece Z., Strumfa I., Abolins A., Vanags A., Gardovskis J. Prognostic factors after curative resection of pancreatic ductal adenocarcinoma: a retrospective study. J. Cancer Therapeutics Res., 2012; DOI: 10.7243/2049-7962-1-27
2011
  • Abolins A., Vanags A., Trofimovics G., Miklasevics E., Gardovskis J., Strumfa I. Molecular subtype shift in breast cancer upon trastuzumab treatment. A case report. Pol. J. Pathol. 2011; 62 (1): 65–68. PMID: 21034437
  • Plakhins G., Irmejs A., Gardovskis A., Subatniece S., Rozīte S., Bitina M., Keire G., Purkalne G., Teibe U., Trofimovičs G., Miklaševičs E., Gardovskis J. Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia. BMC Med Genet. 2011; 12: 147. PMID: 22032251.
  • Abele A., Vjaters E., Irmejs A., Trofimovičs G., Miklaševičs E., Gardovskis J. Epidemiological, clinical and molecular characteristics of hereditary prostate cancer in Latvia. Medicina (Kaunas), 2011; 47 (10): 579-585. PMID: 22186123
  • Kalniete D., Irmejs A., Štrumfa I., Žestkova J., Aksenoka K., Gardovskis J., Miklaševičs E. Detection of Large Deletions and Duplications in Moderate Risk Breast Cancer Susceptibility Genes in Breast Cancer Patients Negative for the BRCA1 and BRCA2 Mutations. Acta Chirurgica Latviensis, 2011;11, (1):3.
  • Abolins A., Vanags A., Strumfa I., Melbarde-Gorkusa I., Abolina M., Trofimovics G., Miklasevics E., Gardovskis J. Primary Breast Lymphoma: Clinical and Morphological Characteristics. Acta Chirurgica Latviensis, 2011;11, (1):9.
  • Maksimenko J., Liepniece-Karele I., Irmejs A., Trofimovics G. The Clinicopathologic Characteristics and Prognostic Significance of Triple - Negative Invasive Breast Cancer Phenotype. Acta Chirurgica Latviensis, 2011;11, (1):16.
  • Abolins A., Strumfa I., Vanags A., Trofimovics G., Gardovskis J. Histological and Immunohistochemical Evaluation of Cytokeratin 5/6 Expressing Breast Cancer. Acta Chirurgica Latviensis, 2011;11, (1):28.
  • Simtniece Z., Vanags A., Strumfa I., Pavars M., Gardovskis J. Prognostic Factors in Potentially Radically Operated Pancreatic Carcinoma. Acta Chirurgica Latviensis, 2011;11, (1):34.
  • Ozolins A., Narbuts Z., Strumfa I., Volanska G., Prieditis P., Stepanovs K., Gardovskis J. Immunocytochemistry as an Adjunct to Fine-needle Aspiration of Thyroid in Distinction Between Benign and Malignant Thyroid Neoplasms. Acta Chirurgica Latviensis, 2011;11, (1):39.
  • Melbarde-Gorkusa I., Strumfa I., Vanags A., Trofimovics G., Gardovskis J. Pathological Features of BRCA1/BRCA2 Mutation-Associated Breast Cancer: Implications for Diagnostics and Treatment. Acta Chirurgica Latviensis, 2011;11, (1): 114–121 DOI: 10.2478/v10163-012-0022-8
  • Vanags A., Grusina-Ujumaza J., Strumfa I., Ambalovs G., Abolins A., Gardovskis J. Primary Bronchus-Associated Lymphoid Tissue (BALT) Lymphoma. Acta Chirurgica Latviensi, 2011; 11 (1): 144–147. DOI: 10.2478/v10163-012-0028-2
  • Melbarde-Gorkusa I., Strumfa I., Irmejs A., Abolins A., Miklasevics E., Gardovskis A., Subatniece S., Trofimovics G., Gardovskis J. Management of BRCA1 Mutation Carrier with Breast Cancer. Acta Chirurgica Latviensis, 2011; 11 (1): 148–150. DOI: 10.2478/v10163-012-0029-1
  • Vanags A., Strumfa I., Abolins A., Brikuns A., Simtniece Z., Gardovskis J. Primary Adenocarcinoma of the Appendix. Acta Chirurgica Latviensis, 2011; 11 (1): 151–153. DOI: 10.2478/v10163-012-0030-8
  • Vjaters E., Strumfa I., Vejins M., Abele A., Trofimovics G., Gardovskis J. Incidental Primary Non-Hodgkin's Lymphoma of the Prostate in a Patient with Prostate Cancer: A Case Report. Acta Chirurgica Latviensi, 2011; 11; (1): 154–155. DOI: 10.2478/v10163-012-0031-7
  • Melbarde-Gorkusa I., Abolins A., Strumfa I., Martinsons A., Gardovskis J. Human Dirofilariasis in Latvia - the First Case in Surgical Practice. Acta Chirurgica Latviensi, 2011; 11 (1): 172–174. DOI: 10.2478/v10163-012-0037-1
2010
  • Dumpis U., Iversen A., Balode A., Saule M., Miklasevics E., Giske CG.: Outbreak of CTX-M-15-producing Klebsiella pneumoniae of sequence type 199 in a Latvian teaching hospital. APMIS, 2010; Vol. 118 (9): 713–716. PMID: 20718724
  • Zavadska D., Berzina D., Drukalska L., Pugacova N., Miklasevics E., Gardovska D. Macrolide resistance in group A beta haemolytic Streptococcus isolated from outpatient children in Latvia. APMIS, 2010; Vol. 118 (5): 366–370. PMID: 20477812
  • Vanags A., Strumfa I., Gardovskis A., Borosenko V., Abolins A., Teibe U., Trofimovics G., Miklasevics E., Gardovskis J. Population screening for hereditary and familial cancer syndromes in Valka district of Latvia. Hered. Cancer Clin. Pract., 2010; 8 (1):8. PMID: 21034437
  • Ozolins A., Narbuts Z., Strumfa I., Volanska G., Gardovskis J. Diagnostic utility of immunohistochemical panel in various thyroid pathologies. Langenbecks Arch Surg., 2010; 395(7):885–891. PMID: 20640858
  • Vanags A., Strumfa I., Gardovskis A., Melbarde-Gorkusa I., Abolins A., Trofimovics G., Gardovskis J. The Characteristics of Hereditary Colorectal Cancer Syndromes by Population Screening. Acta Chirurgica Latviensis, 2010; 10 (2):3–8. DOI: 10.2478/v10163-011-0001-5
  • Vanags A., Strumfa I., Gardovskis A., Melbarde-Gorkusa I., Abolins A., Trofimovics G., Gardovskis J. The Upgrade of Hereditary Cancer Surveillance Schedule by Valka District Population Screening Data. Acta Chirurgica Latviensis, 2010; 10 (2). DOI: 10.2478/v10163-011-0002-4
  • Vanags A., Strumfa I., Abolins A., Gardovskis A., Melbarde-Gorkusa I., Trofimovics G., Gardovskis J. The Concept, Diagnostics, Surgical Prevention and Treatment of Hereditary Colorectal Cancer in Nowadays Medicine. Acta Chirurgica Latviensis, 2010; 10 (2):80–85. DOI: 10.2478/v10163-011-0016-y
  • Ozolins A., Narbuts Z., Strumfa I., Prieditis P., Gardovskis J. Diagnosis and Management of the Thyroid Nodules. Acta Chirurgica Latviensis, 2010; 10 (2):86–90. DOI: 10.2478/v10163-011-0017-x
  • Abolins A., Vanags A., Volanska G., Melbarde-Gorkusa I., Strumfa I., Trofimovics G., Gardovskis J. Malignant Peripheral Nerve Sheath Tumour of the Breast in Complex Clinical Background. Acta Chirurgica Latviensis, 2010; 10 (2). DOI: 10.2478/v10163-011-0022-0
  • Cupane L., Pugacova N., Aleksejevs G., Berzina D., Gardovska D., Miklasevics E. Methicillin Susceptible Panton - Valentine Leukocidin Positive S. Aureus Pneumonia in a Child with Novel Influenza H1N1 Infection. Acta Chirurgica Latviensis. 2010; 10 (2):127–130. DOI: 10.2478/v10163-011-0027-8

Equipment

1111_RTU_use_science_logo_big.png